SEC Filings

SEC Filings

Filing date	Description	Form	View
Oct 12, 2017	Statement of changes in beneficial ownership of securities	4	View HTML 0001686266-17-000016.pdf 0001686266-17-000016.rtf
Oct 17, 2017		D	View HTML 0001686266-17-000017.pdf 0001686266-17-000017.rtf
Oct 23, 2017	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-17-063361.pdf 0001104659-17-063361.rtf 0001104659-17-063361.xls
Oct 30, 2017	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-17-064639.pdf 0001104659-17-064639.rtf 0001104659-17-064639.xls
Nov 02, 2017	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-17-006341.pdf 0001214659-17-006341.rtf 0001214659-17-006341.xls
Nov 02, 2017	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-17-006342.pdf 0001214659-17-006342.rtf 0001214659-17-006342.xls
Nov 02, 2017	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-17-006343.pdf 0001214659-17-006343.rtf 0001214659-17-006343.xls
Nov 02, 2017	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-17-006344.pdf 0001214659-17-006344.rtf 0001214659-17-006344.xls
Nov 02, 2017	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-17-006345.pdf 0001214659-17-006345.rtf 0001214659-17-006345.xls
Nov 06, 2017	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001047469-17-006801.pdf 0001047469-17-006801.rtf 0001047469-17-006801.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE